Getting the annual RSV shot and other important vaccines is a fantastic way to safeguard yourself and your family as winter ...

The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years ...

Regarding hospitalizations among immunocompetent older adults, vaccine effectiveness was 83% for the GSK vaccine and 73% for ...

The other group at the highest risk when it comes to RSV is children under age five, and specifically infants—especially ...

Respiratory syncytial virus (RSV) caused significant hospitalizations and severe outcomes in adults, especially those aged 75 ...

In this cross-sectional study of adults hospitalized with respiratory syncytial virus (RSV) before the 2023 introduction of RSV vaccines, RSV was associated with substantial burden of hospitalizations ...

A new study published today in JAMA Network Open shows that respiratory syncytial virus (RSV) was associated with a ...

Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...

Since their introduction last year, researchers have been monitoring the real-world impact of the new respiratory syncytial ...

Australia will fund free RSV vaccines for newborns and pregnant women starting in 2025, aiming to protect vulnerable groups ...

Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...